Patent & IP news for May 1, 2017

Monday Miscellany from ipkitten.blogspot.com

Purring on happiness
because of so many IP events!The Seminar Second-hand Markets for Digital Copies – An EU copyright chimera?, featuring IPKat Eleonora Rosati as speaker, will take place on 5 May 2017 at the ...

Share via E–mail | Twitter | Facebook

IP Musings: Filing the Friendly Replies from patentlyo.com

The primary author of this month’s IP Musings is John Voisinet along with Ji-Yong (David) Chung. John is a patent agent at Snyder, Clark, Lesch & Chung where David is a partner. David.Chung@snyderllp ...

Share via E–mail | Twitter | Facebook

97% of Europeans regard IP rights favorably; 41% ages 15-24 believe it is sometimes OK to buy counterfeits from ipcloseup.com

When it comes to intellectual property rights Europeans are highly respectful, except among the young, where buying counterfeits has gown. That is the primary take-away of an extensive European Community survey of attitudes toward IP ...

Share via E–mail | Twitter | Facebook

WIPO Copyright Committee This Week: Broadcasting, Exceptions, Resale Rights, Digital Environment from www.ip-watch.org

A packed week is underway for the World Intellectual Property Organization copyright committee. Delegates are hoping to find agreement on core principles of a treaty protecting broadcasting organisations’ rights, and continue work on possible limitations ...

Share via E–mail | Twitter | Facebook

IPR Request and Post-Institution Fees Not Recoverable as Costs in Related District Court Case from docketreport.blogspot.com

Following inter partes review that invalidated plaintiff's patent, the court denied defendant's motion to tax $23,000 in IPR request and post-institution fees as costs. "Defendant has raised an issue of first impression ...

Share via E–mail | Twitter | Facebook

New R&D Funding Model For TB, Antimicrobial Resistance from www.ip-watch.org

The World Health Organization Bulletin this month has an article about the need for new models of research and development for tuberculosis and antimicrobial resistance. The article describes a new funding framework called the 3P ...

Share via E–mail | Twitter | Facebook

CAFC in Helsinn v. Teva. AIA did NOT change meaning of "on sale." Invention can be ready for patenting before FDA approval. from ipbiz.blogspot.com



The issue in Helsinn v. Teva was the possible invalidating effect of
a sale before the critical date:


The patents-in-suit purport
to disclose novel intravenous formulations using
unexpectedly low concentrations of palonosetron that
were not ...

Share via E–mail | Twitter | Facebook

Recognicorp, LLC v. Nintendo Co. (Fed. Cir. 2017) from www.patentdocs.org

By Michael Borella -- Recognicorp, owner of U.S. Patent No. 8,005,303, sued Nintendo for infringement in the U.S. District Court for the District of Oregon. After a transfer to the U.S ...

Share via E–mail | Twitter | Facebook